What is Ruxolitinib?

Ruxolitinib is a drug used to manage and treat myelofibrosis (PMF), polycythemia vera, and steroid-refractory acute graft-versus-host disease. It belongs to the Janus kinase inhibitor class of drugs and works by competitively inhibiting the ATP-binding catalytic sites of JAK1 and JAK2. The result of this inhibition is disruption of cytokine and growth factor signaling pathways, leading to a decrease in pro-inflammatory cytokines and chemokines that are often elevated in myelofibrosis and other inflammatory diseases.

Ruxolitinib is taken orally and is available as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg tablets, and its recommended dosage is based on the patient's individual condition and blood results. For example, in the treatment of myelofibrosis, the dosage is based on the patient's baseline platelet count. Myelofibrosis patients with platelet counts between 50 and 100x10^9/L can take up to 5 mg twice daily, while patients with platelet counts above 100x10^9/L can take up to 15 mg twice daily.

The original drug of ruxolitinib tablets has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. SpecificationsThe price of each box of 5mg*60 tablets may be around 3,000 yuan. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.